enVVeno Medical (NASDAQ:NVNO) Issues Quarterly Earnings Results

enVVeno Medical (NASDAQ:NVNO) announced its earnings results on Friday. The company reported ($0.23) earnings per share for the quarter, Zacks reports.

enVVeno Medical Stock Performance

Shares of NASDAQ:NVNO opened at $0.70 on Friday. The company has a market capitalization of $13.57 million, a PE ratio of -0.59 and a beta of 0.94. The stock has a fifty day moving average of $0.83 and a 200-day moving average of $2.82. enVVeno Medical has a one year low of $0.62 and a one year high of $5.62.

Analysts Set New Price Targets

NVNO has been the topic of several research analyst reports. LADENBURG THALM/SH SH cut shares of enVVeno Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 21st. Wall Street Zen cut enVVeno Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of enVVeno Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Hedge Funds Weigh In On enVVeno Medical

A number of hedge funds and other institutional investors have recently modified their holdings of NVNO. Perceptive Advisors LLC purchased a new position in shares of enVVeno Medical in the second quarter worth approximately $5,127,000. Creative Planning acquired a new position in enVVeno Medical in the 2nd quarter worth approximately $54,000. Jane Street Group LLC acquired a new stake in enVVeno Medical during the 2nd quarter valued at $51,000. Finally, Geode Capital Management LLC raised its stake in enVVeno Medical by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after purchasing an additional 2,211 shares during the period. Institutional investors and hedge funds own 34.71% of the company’s stock.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).